{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:28:48Z","timestamp":1794097728768,"version":"4.8.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients taking SGLT-2 inhibitors may experience delayed peritoneal fibrosis, better ultrafiltration of water and toxins, and higher survival rates. We aimed to evaluate the possible effects of Dapagliflozin in changing the peritoneal solute transfer rate, reducing peritoneal glucose absorption, and, hence, increasing ultrafiltration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodology<\/jats:title>\n                <jats:p>A pilot pre-post interventional study was used to evaluate 20 patients on continuous ambulatory peritoneal dialysis (CAPD) enrolled in a one-month self-controlled study [Trial#: NCT04923295]. Inclusion criteria included being over 18, and having a Peritoneal Dialysis (PD) vintage of at least six months. All participants were classified as having high or average high transport status based on their Peritoneal Equilibrium Test with a D0\/D4\u2009&gt;\u20090.39. and using at least two exchanges with 2.35% dextrose over the previous three months before enrollment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Following the treatment, 13 patients had an increase in median D4\/D0 from 0.26 [0.17\u20130.38] to 0.31 [0.23\u20130.40], while seven patients had a decline\u00a0from 0.28 [0.17\u20130.38] to 0.23 [0.14\u20130.33]. Additionally, nine patients had a decrease in median D\/P from 0.88 [0.67\u20130.92] to 0.81 [0.54\u20130.85], while 11 patients had an increase from 0.70 [0.6\u20130.83] to 0.76 [0.63\u20130.91].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>According to the findings of this study, Dapagliflozin usage in peritoneal dialysis patients did not result in a reduction in glucose absorption across the peritoneal membrane. Additionally, Dapagliflozin was also associated with a small increase in sodium dip, a decrease in peritoneal VEGF, and a decrease in systemic IL-6 levels all of which were not statistically significant. Further large-scale studies are required to corroborate these conclusions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03429-2","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T10:02:24Z","timestamp":1706263344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-0699","authenticated-orcid":false,"given":"Zakaria","family":"Hamdan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusri","family":"Abdel-Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Enaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Sarsour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Kharraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2655-6109","authenticated-orcid":false,"given":"Zaher","family":"Nazzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"3429_CR1","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1681\/ASN.2016010112","volume":"27","author":"R Mehrotra","year":"2016","unstructured":"Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016;27:3238.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"3429_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/089686080902902S17","volume":"29","author":"AM Cueto-Manzano","year":"2009","unstructured":"Cueto-Manzano AM. Rapid solute transport in the peritoneum: physiologic and clinical consequences. Perit Dial Int J Int Soc Perit Dial. 2009;29(Suppl 2):90\u20135.","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"3429_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/089686088700700306","volume":"7","author":"ZJT Karl","year":"1987","unstructured":"Karl ZJT, Khanna ONR, Leonor BFP, et al. Peritoneal equilibration test. Perit Dial Int. 1987;7:138\u201348.","journal-title":"Perit Dial Int"},{"key":"3429_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/089686080502500502","volume":"25","author":"T Sitter","year":"2005","unstructured":"Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: saint or sinner? Perit Dial Int J Int Soc Perit Dial. 2005;25:415\u201325.","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"3429_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000368972","volume":"39","author":"I Teitelbaum","year":"2015","unstructured":"Teitelbaum I. Ultrafiltration failure in peritoneal dialysis: a pathophysiologic approach. Blood Purif. 2015;39:70\u20133. https:\/\/doi.org\/10.1159\/000368972.","journal-title":"Blood Purif"},{"key":"3429_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001912","author":"S Mujais","year":"2006","unstructured":"Mujais S, Story K. Peritoneal dialysis in the US: evaluation of outcomes in contemporary cohorts. Kidney Int Suppl. 2006. https:\/\/doi.org\/10.1038\/sj.ki.5001912.","journal-title":"Kidney Int Suppl"},{"key":"3429_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/biom10111573","volume":"10","author":"MS Balzer","year":"2020","unstructured":"Balzer MS, Rong S, Nordlohne J, et al. SGLT2 inhibition by Intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate. Biomolecules. 2020;10:1573. https:\/\/doi.org\/10.3390\/biom10111573.","journal-title":"Biomolecules."},{"key":"3429_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.biopha.2018.10.106","volume":"109","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Fan J, Zheng C, et al. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2. Biomed Pharmacother. 2019;109:1327\u201338. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.106.","journal-title":"Biomed Pharmacother"},{"key":"3429_CR9","doi-asserted-by":"publisher","first-page":"e8596","DOI":"10.1590\/1414-431X20198596","volume":"52","author":"RF Romani","year":"2019","unstructured":"Romani RF, Waniewski J, Kruger L, et al. Comparison of three PET methods to assess peritoneal membrane transport. Braz J Med Biol Res. 2019;52:e8596. https:\/\/doi.org\/10.1590\/1414-431X20198596.","journal-title":"Braz J Med Biol Res"},{"key":"3429_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12882-023-03164-8","volume":"24","author":"J-W Lai","year":"2023","unstructured":"Lai J-W, Lin H-J, Chou C-Y. SGLT-2 inhibitors may increase ultrafiltration in incident peritoneal dialysis patients: a case report. BMC Nephrol. 2023;24:106. https:\/\/doi.org\/10.1186\/s12882-023-03164-8.","journal-title":"BMC Nephrol"},{"key":"3429_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000520894","volume":"47","author":"S Schricker","year":"2022","unstructured":"Schricker S, Oberacker T, Fritz P, et al. Peritoneal expression of SGLT-2, GLUT1, and GLUT3 in peritoneal dialysis patients. Kidney Blood Press Res. 2022;47:125\u201334. https:\/\/doi.org\/10.1159\/000520894.","journal-title":"Kidney Blood Press Res"},{"key":"3429_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26502\/anu.2644-2833047","volume":"5","author":"AK Alhwiesh","year":"2022","unstructured":"Alhwiesh AK, Abdul-Rahman IS, Nasreldin MA, et al. The use of SGLT2 inhibitors in peritoneal dialysis patients: a shade of light on dapagliflozin. Arch Nephrol Urol. 2022;5:1\u20138.","journal-title":"Arch Nephrol Urol."},{"key":"3429_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1056\/NEJMoa2034279","volume":"385","author":"J Morelle","year":"2021","unstructured":"Morelle J, Marechal C, Yu Z, et al. AQP1 promoter variant, water transport, and outcomes in peritoneal dialysis. N Engl J Med. 2021;385:1570\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2034279.","journal-title":"N Engl J Med"},{"key":"3429_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/sj.ki.5000183","volume":"69","author":"V La Milia","year":"2006","unstructured":"La Milia V, Pozzoni P, Virga G, et al. Peritoneal transport assessment by peritoneal equilibration test with 3.86% glucose: a long-term prospective evaluation. Kidney Int. 2006;69:927\u201333. https:\/\/doi.org\/10.1038\/sj.ki.5000183.","journal-title":"Kidney Int"},{"key":"3429_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2215\/CJN.15371121","volume":"17","author":"RT Krediet","year":"2022","unstructured":"Krediet RT, Parikova A. Relative contributions of pseudohypoxia and inflammation to peritoneal alterations with long-term peritoneal dialysis patients. Clin J Am Soc Nephrol. 2022;17:1259\u201366. https:\/\/doi.org\/10.2215\/CJN.15371121.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3429_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/08968608211004683","volume":"42","author":"Y Shi","year":"2022","unstructured":"Shi Y, Hu Y, Cui B, et al. Vascular endothelial growth factor-mediated peritoneal neoangiogenesis in peritoneal dialysis. Perit Dial Int J Int Soc Perit Dial. 2022;42:25\u201338. https:\/\/doi.org\/10.1177\/08968608211004683.","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"3429_CR17","doi-asserted-by":"publisher","first-page":"e13335","DOI":"10.1111\/ijcp.13335","volume":"73","author":"Y Aso","year":"2019","unstructured":"Aso Y, Kato K, Sakurai S, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019;73:e13335. https:\/\/doi.org\/10.1111\/ijcp.13335.","journal-title":"Int J Clin Pract"},{"key":"3429_CR18","doi-asserted-by":"publisher","first-page":"ehac544.2683","DOI":"10.1093\/eurheartj\/ehac544.2683","volume":"43","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Sagris M, Oikonomou E, et al. Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents. Eur Heart J. 2022;43:ehac544.2683. https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.2683.","journal-title":"Eur Heart J"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03429-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03429-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03429-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T10:03:18Z","timestamp":1706263398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03429-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3429"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03429-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"9 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study complied with the institutional and\/or national research committee ethical standards and the 1964 Helsinki declaration and subsequent amendments or equivalent ethical standards. The study was approved by the Institutional Review Board (IRB) of An-Najah National University [Reference#: Med. April 2021\/13], and appropriate permissions were taken from the hospitals. After thoroughly explaining\u00a0the project's aims and objectives, participants were invited to participate in the study voluntarily. They were further informed that their personal information would be used solely for research purposes and that strict confidentiality would be maintained. Every participant signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u201cNot applicable\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}